Voya Investment Management LLC Sells 21,244 Shares of LivaNova PLC $LIVN

Voya Investment Management LLC trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 17.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 99,254 shares of the company’s stock after selling 21,244 shares during the period. Voya Investment Management LLC owned about 0.18% of LivaNova worth $5,199,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock valued at $28,000 after buying an additional 407 shares during the period. State of Wyoming bought a new stake in shares of LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its holdings in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the period. Parallel Advisors LLC grew its position in LivaNova by 1,312.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after acquiring an additional 958 shares during the last quarter. Finally, Strs Ohio bought a new position in LivaNova in the 1st quarter valued at $130,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LIVN has been the subject of several research analyst reports. Robert W. Baird set a $75.00 target price on LivaNova in a research report on Tuesday, December 16th. KeyCorp started coverage on shares of LivaNova in a research note on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Finally, Mizuho raised their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.63.

LivaNova Stock Performance

LIVN stock opened at $63.13 on Friday. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $65.57. The business has a 50-day moving average price of $58.12 and a 200 day moving average price of $52.72. The company has a market capitalization of $3.45 billion, a P/E ratio of -15.78 and a beta of 1.02. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.